Lakefront Biotherapeutics (LKFT) Payables (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Payables data on file, last reported at $112.1 million in Q1 2026.

• Payables for Q1 2026 came in at $112.1 million, down 36.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.1 million (down 36.91% YoY), and the FY2025 annual result was $121.8 million, up 77.48% from the prior year.
• Payables retreated to $112.1 million in Q1 2026 per LKFT's latest filing, from $121.8 million in the prior quarter.
• Over five years, Payables peaked at $177.7 million in Q1 2025 and troughed at $68.6 million in Q4 2024.
• A 5-year average of $137.0 million and a median of $144.9 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables plunged 52.63% in 2024, then jumped 77.48% in 2025.
• A 5-year view of Payables shows it stood at $151.7 million in 2022, then decreased by 4.49% to $144.9 million in 2023, then sank by 52.63% to $68.6 million in 2024, then jumped by 77.48% to $121.8 million in 2025, then declined by 7.96% to $112.1 million in 2026.
• Business Quant data shows LKFT's Payables at $112.1 million in Q1 2026, $121.8 million in Q4 2025, and $117.6 million in Q3 2025.